Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Conference News AHA 2018

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2016

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

L.A. McKeown

November 17, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Conference News AHA 2014

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

November 16, 2014

Advertisement

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

ApoB Gains Ground as Best Lipid Predictor of MI Risk

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content